IPG1094

Nanjing Immunophage Biotech Co., Ltd · Phase 1 active Small molecule

At a glance

Generic name	IPG1094
Sponsor	Nanjing Immunophage Biotech Co., Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients (PHASE1, PHASE2)
Study of IPG1094 in Healthy Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IPG1094 CI brief — competitive landscape report
IPG1094 updates RSS · CI watch RSS
Nanjing Immunophage Biotech Co., Ltd portfolio CI